Ruxolitinib in Patients With Myelofibrosis

Sponsor
Assiut University
Study ID
NCT05762874
Status
Unknown

Conditions

  • Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Prospective study to evaluate the response of myelofibrosis patients to ruxolitinib and it's adverse events on patients (1 year observational study).

Key Dates

Start date
Mar 31, 2023
Status verified
Feb 2023
Primary completion
Mar 31, 2025
Completion
Jun 30, 2025

Study Design

Enrollment
51 participants (estimated)

Primary Outcome Measure

decrease of spleen size [ Time Frame: 6 months ]

Central Contacts

Related Studies